Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: Regulation and therapeutic implications

• Published in: Journal of molecular and cellular cardiology Vol. 75; pp. 199 - 205
• Main Authors: Ichiki, Tomoko, Schirger, John A., Huntley, Brenda K., Brozovich, Frank V., Maleszewski, Joseph J., Sandberg, Sharon M., Sangaralingham, S. Jeson, Park, Soon J., Burnett, John C.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.10.2014
• Subjects: Adult; Cardiovascular; Collagen Type I - genetics; Collagen Type I - metabolism; Female; Fibrosis; Guanylate Cyclase - metabolism; Heart failure; Heart Failure - enzymology; Heart Failure - pathology; Heart Failure - therapy; Heart Ventricles - metabolism; Heart Ventricles - pathology; Heart-assist device; Humans; Male; Middle Aged; Myocardium - metabolism; Myocardium - pathology; Natriuretic Peptide, Brain - genetics; Natriuretic Peptide, Brain - metabolism; Natriuretic peptides; Receptors, Atrial Natriuretic Factor - genetics; Receptors, Atrial Natriuretic Factor - metabolism; RNA, Messenger - genetics; RNA, Messenger - metabolism; Heart failure; Col; NP; cGMP; LV; LVAD; CFs; TGF; NPR-C; Fibrosis; GC; Heart-assist device; HF; Natriuretic peptides; heart failure; cyclic guanosine monophosphate; natriuretic peptide receptor C; cardiac fibroblasts; left ventricle; collagen; natriuretic peptide; TGF beta-1; guanylyl cyclase; left ventricular assist device

Left ventricular assist device (LVAD) support has been used in the treatment of end-stage heart failure (HF), however use of anti-fibrotic co-therapies may improve prognosis. Natriuretic peptides (NPs) possess anti-fibrotic properties through their receptors, GC-A/GC-B/NPR-C. We sought to evaluate c...